• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Personalized Medicine >Clinical Utility of Gene Expression Profiling Data for Clinical Decision-Making Regarding Adjuvant Therapy in Early Stage, Node-Negative Breast Cancer: A Case Report
【24h】

Clinical Utility of Gene Expression Profiling Data for Clinical Decision-Making Regarding Adjuvant Therapy in Early Stage, Node-Negative Breast Cancer: A Case Report

机译：基因表达谱数据在早期结节阴性乳腺癌辅助治疗中的临床决策中的临床应用：一例报告

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Breast cancer is the most common malignancy among women in the United States with the second highest incidence of cancer-related death following lung cancer. The decision-making process regarding adjuvant therapy is a time intensive dialogue between the patient and her oncologist. There are multiple tools that help individualize the treatment options for a patient. Population-based analysis with Adjuvant! Online and genomic profiling with Oncotype DX are two commonly used tools in patients with early stage, node-negative breast cancer. This case report illustrates a situation in which the population-based prognostic and predictive information differed dramatically from that obtained from genomic profiling and affected the patient’s decision. In light of this case, we discuss the benefits and limitations of these tools.
机译：乳腺癌是美国女性中最常见的恶性肿瘤，其癌症相关死亡的发生率仅次于肺癌，位居第二。有关辅助治疗的决策过程是患者与肿瘤科医生之间的时间密集对话。有多种工具可帮助个性化患者的治疗选择。使用佐剂进行基于人群的分析！ Oncotype DX的在线和基因组图谱分析是早期淋巴结阴性乳腺癌患者的两种常用工具。该病例报告说明了一种情况，其中基于人群的预后和预测信息与从基因组分析中获得的信息大相径庭，并影响了患者的决定。鉴于这种情况，我们讨论了这些工具的优点和局限性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号